RxDoctor Payments DataLook up a doctor →

George Raad, MD

Family Medicine · Charlotte, NCNPI 1679513998

Payments from drug & device makers

$7,667,617in general payments, 2019–2025

Across 1,701 payments — averaging $4507.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5.8M
  • Bavarian Nordic A/s$848K
  • AbbVie$390K
  • GSK$156K
  • AstraZeneca$138K
  • Regeneron$86K
  • plus $254K from 54 others

What the payments were for

  • Travel & lodging$7975%
  • Food & beverage$14,70292%
  • Education$4213%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer480$5,796,221
Bavarian Nordic A/s65$848,109
AbbVie(2 entities)217$389,601
GSK89$156,018
AstraZeneca104$138,133
Regeneron38$85,521
BD5$65,041
Sanofi US Services Inc.5$59,535
Eli Lilly9$56,284
Lexicon Pharmaceuticals, Inc.1$33,015
Evofem Biosciences, Inc.9$17,009
Ferring International Pharmascience Center US4$7,499
Astrazeneca UK Limited10$4,644
Novo Nordisk101$1,261
Lilly USA, LLC71$1,118
Astellas Pharma US Inc37$987
Sanofi-aventis U.S. LLC41$779
Johnson & Johnson44$665
Boehringer Ingelheim41$658
Takeda Pharmaceuticals U.S.A., Inc.33$571
Merck33$496
Novartis26$448
Abbott20$283
Kowa Pharmaceuticals America, Inc.20$280
Alkermes, Inc.13$255
Amgen16$243
Otsuka America Pharmaceutical, Inc.13$242
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$210
Bayer13$199
Exact Sciences9$177
Orexo US, Inc.10$157
Mylan Specialty L.p.9$153
Sumitomo Pharma America, Inc.8$153
Arbor Pharmaceuticals, Inc.11$147
Bausch Health US, LLC9$146
Lundbeck LLC8$144
Esperion Therapeutics, Inc.5$110
Alfasigma USA, Inc.1$95
Amarin Pharma, Inc.6$93
Forte Bio-pharma LLC4$91
Supernus Pharmaceuticals, Inc.3$74
Xeris Pharmaceuticals, Inc.4$66
Avanir Pharmaceuticals, Inc.4$55
E.r. Squibb & Sons, L.L.C.4$50
Ardelyx, Inc.3$50
Cvrx, Inc.2$43
Tonix Medicines, Inc.2$42
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$42
Hikma Pharmaceuticals USA2$36
Braeburn Inc.2$35
Shield Therapeutics Inc2$35
Azurity Pharmaceuticals, Inc.2$33
Almatica Pharma LLC2$32
Eisai Inc.2$28
Shire North American Group Inc2$26
Scilex Pharmaceuticals Inc.2$25
Axsome Therapeutics, Inc.1$23
Ironwood Pharmaceuticals, Inc1$20
USWM, LLC1$18
Pear Therapeutics (US), Inc.1$17

How this compares

$7,667,617 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$43,590
Medicare patients
166
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$63,059
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl432$62,089
EliquisApixaban72$56,719
MounjaroTirzepatide42$44,091
XareltoRivaroxaban63$34,090
Soliqua 100-33Insulin Glargine/Lixisenatide22$30,995
FarxigaDapagliflozin Propanediol28$30,974
JardianceEmpagliflozin38$30,562
JanumetSitagliptin Phos/Metformin Hcl21$26,743
LinzessLinaclotide39$25,118
RybelsusSemaglutide12$24,806
SuboxoneBuprenorphine Hcl/Naloxone Hcl36$23,491
JanuviaSitagliptin Phosphate21$21,497
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,069
EntrestoSacubitril/Valsartan17$15,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,261$87,86565 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$36$62,089432 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Synjardy Xr$658$57,703100 claims
PfizerEliquis$5,796,221$56,71972 claims
MerckJanumet, Januvia, Janumet Xr$496$54,66153 claims
Lilly USA, LLCMounjaro$1,118$44,09142 claims
AstraZenecaFarxiga, Symbicort$138,133$38,13156 claims
Johnson & JohnsonXarelto$665$34,09063 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$779$30,99522 claims
AbbVieLinzess$389,601$25,11839 claims
GSKTrelegy Ellipta$156,018$21,06924 claims
NovartisEntresto$448$15,10217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →